EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Lam, Thomas B.L. (Aberdeen Royal Infirmary)
MacLennan, Steven (University of Aberdeen)
Willemse, Peter-Paul M. (University Medical Center Utrecht)
Mason, Malcolm D. (Velindre Cancer Centre)
Plass, Karin (EAU Guidelines Office)
Shepherd, Robert (EAU Guidelines Office)
Baanders, Ruud
Bangma, Chris H. (Erasmus University Medical Centre)
Bjartell, Anders (Lund University)
Bossi, Alberto (Gustave Roussy Institute)
Briers, Erik
Briganti, Alberto (IRCCS Ospedale San Raffaele (Milà, Itàlia))
Buddingh, Karel T. (HagaZiekenhuis)
Catto, James W.F. (Royal Hallamshire Hospital)
Colecchia, Maurizio (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano)
Cox, Brett W. (Zucker School of Medicine)
Cumberbatch, Marcus G. (University of Sheffield)
Davies, Jeff
Davis, Niall F. (Royal College of Surgeons in Ireland)
De Santis, Maria (Charité University Hospital)
Dell'Oglio, Paolo (ORSI Academy)
Deschamps, André (Europa Uomo)
Donaldson, James F. (Aberdeen Royal Infirmary)
Egawa, Shin (Jikei University School of Medicine)
Fankhauser, Christian D. (University of Zurich)
Fanti, Stefano (University of Bologna)
Fossati, Nicola (Scientific Institute and University Vita-Salute San Raffaele Hospital)
Gandaglia, Giorgio (IRCCS Ospedale San Raffaele)
Gillessen, Silke (University of Bern)
Grivas, Nikolaos (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Gross, Tobias (University of Bern)
Grummet, Jeremy P. (Monash University)
Henry, Ann M. (St. James's University Hospital)
Ingels, Alexandre (Henri Mondor Hospital)
Irani, Jacques (University Hospital of Bicêtre-Paris Sud-Saclay University)
Lardas, Michael (Department of Reconstructive Urology and Surgical Andrology)
Liew, Matthew (Wigan and Leigh NHS Foundation Trust)
Lin, Daniel W. (University of Washington)
Moris, Lisa (KU Leuven)
Omar, Muhammad Imran (University of Aberdeen)
Pang, Karl H. (University of Sheffield)
Paterson, Catherine C. (Robert Gordon University)
Renard-Penna, Raphaële (Sorbonne Université)
Ribal, María J. (Hospital Clínic i Provincial de Barcelona)
Roobol, M.J. (Erasmus University Medical Centre)
Rouprêt, Morgan (Sorbonne Université)
Rouvière, Olivier (Université de Lyon)
Sancho-Pardo, Gemma (Institut d'Investigació Biomèdica Sant Pau)
Richenberg, Jonathan (Brighton And Sussex University Hospitals NHS Trust (Brighton, Regne Unit))
Schoots, Ivo G. (Erasmus University Medical Center)
Sedelaar, J.P.Michiel (Radboud University Medical Centre)
Stricker, Phillip (Garvan Institute of Research)
Tilki, Derya (University Hospital Hamburg-Eppendorf)
Vahr Lauridsen, Susanne (Copenhagen University Hospital)
van den Bergh, Roderick C.N. (St. Antonius Hospital)
Van den Broeck, Thomas (University Hospitals Leuven (Bèlgica))
van der Kwast, Theodorus H. (Erasmus University Medical Center)
van der Poel, Henk G. (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
van Leenders, Geert J.L.H. (Erasmus University Medical Center)
Varma, Murali (University Hospital of Wales)
Violette, Philippe D. (McMaster University (Canadà))
Wallis, Christopher J.D. (Vanderbilt University Medical Center)
Wiegel, Thomas (University Hospital of Ulm (Alemanya))
Wilkinson, Karen (University College London Hospitals)
Zattoni, Fabio (Academic Medical Centre Hospital)
N'Dow, James M.O. (Aberdeen Royal Infirmary)
Van Poppel, Hendrik (University Hospitals Leuven (Bèlgica))
Cornford, Philip (Royal Liverpool and Broadgreen Hospitals NHS Trust)
Mottet, Nicolas (University Hospital Jean Monnet)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. To develop consensus statements for all domains of DAT. A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Active surveillance and monitoring ; Clinical practice guidelines ; Consensus group meeting ; Consensus statements ; Deferred treatment with curative intent ; Delphi survey ; Eligibility ; Follow-up ; Localised prostate cancer ; Outcome measures ; Reclassification
Publicat a:	European Urology, Vol. 76 Núm. 6 (december 2019) , p. 790-813, ISSN 1873-7560

DOI: 10.1016/j.eururo.2019.09.020
PMID: 31587989

28 p, 397.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats